Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
- JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck
October 19, 2011
- UCB Japan Reorganizes Sales & Marketing Division to Enhance Specialization
October 19, 2011
- SSP Aims for 10% Market Share with Switch OTC Alesion 10
October 19, 2011
- Japan, a Strategic Country Where Growth is Expectable: New AZ President Hudson
October 18, 2011
- MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
- MTPC Aims to Initiate Clinical Studies for 3 Compounds per Year
October 18, 2011
- Torii Upwardly Revises Profit Forecast for 1st Half of FY2012
October 18, 2011
- Eisai, Johns Hopkins Univ. Agree on Neurological Drug Discovery Collaboration
October 18, 2011
- OncoTherapy Science to Start Clinical Trial for Cancer Treatment Antibody in France
October 18, 2011
- Takeda Appoints Davidsen Head of Emerging Markets, Nycomed
October 18, 2011
- R-Tech Ueno to Resume Development of Treatment for Dry Eye
October 18, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…